| Followers | 0 |
| Posts | 2177 |
| Boards Moderated | 0 |
| Alias Born | 04/13/2018 |
Tuesday, August 03, 2021 5:01:40 PM
It Does Not Require A World Class Maven.
All it takes is understanding why the HIV BLA was rejected. It wasn't for not reducing the viral load. At first it was the self injecting device and lack of 700mg data. Then Nader admitted there was more like Receptor Occupancy issues.
As for its failure as a COVID drug well that's simple to. It did not show any clinical significance in any of it's COVID trials. Anecdotally it sounds great, but for some reason the anecdotal results don't replicate in a clinical environment? Well that's because you don't know how many people received the drug under EINDs, how many actually got better, how many died, and how many remained in need of care. You just have stories that can get trotted out with no real stats to back it up. As such Nader and CYDY is now subject to a major federal investigation because they did a lot of bullshitting.
As for the other uses of the drug and PI and PII results. When has CYDY not claimed stellar results in those phases? There is a pattern here that is being willfully ignored.
Then we are back to the claims that CYDY had statistical significance. The strange claim made by Nader that it was 84% effective after first claiming it wasn't. Followed by the FDA having to come out and say the drug has not shown clinical significance and Nader having to own his lies.
Well we don't have Stat Sig. Maybe in the future if something changed in the Brazil trials, but we have the same crew running the show so I'm not holding out hope.
All the arguments surrounding CYDY being a wonder company with a wonder drug revolve around a lot of emotion. A lot of people sunk money into this company on promises Nader has yet to make good on. So I have zero surprise that scientific method, objectivism and logic got thrown out the window. Money and emotions are running high.
All it takes is understanding why the HIV BLA was rejected. It wasn't for not reducing the viral load. At first it was the self injecting device and lack of 700mg data. Then Nader admitted there was more like Receptor Occupancy issues.
As for its failure as a COVID drug well that's simple to. It did not show any clinical significance in any of it's COVID trials. Anecdotally it sounds great, but for some reason the anecdotal results don't replicate in a clinical environment? Well that's because you don't know how many people received the drug under EINDs, how many actually got better, how many died, and how many remained in need of care. You just have stories that can get trotted out with no real stats to back it up. As such Nader and CYDY is now subject to a major federal investigation because they did a lot of bullshitting.
As for the other uses of the drug and PI and PII results. When has CYDY not claimed stellar results in those phases? There is a pattern here that is being willfully ignored.
Then we are back to the claims that CYDY had statistical significance. The strange claim made by Nader that it was 84% effective after first claiming it wasn't. Followed by the FDA having to come out and say the drug has not shown clinical significance and Nader having to own his lies.
Well we don't have Stat Sig. Maybe in the future if something changed in the Brazil trials, but we have the same crew running the show so I'm not holding out hope.
All the arguments surrounding CYDY being a wonder company with a wonder drug revolve around a lot of emotion. A lot of people sunk money into this company on promises Nader has yet to make good on. So I have zero surprise that scientific method, objectivism and logic got thrown out the window. Money and emotions are running high.
Recent CYDY News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
